Indian drugmaker Cipla misses third-quarter profit view

Jan 23 (Reuters) - Cipla CIPL.NS, India's third-largest drugmaker by revenue, reported quarterly profit below estimates on Friday, dragged by a production halt at the exclusive manufacturer of its no. 2 revenue contributor tumour drug Lanreotide.

The company, which makes the popular Asthalin inhaler and the Cofsils cough drops, reported consolidated net profit slumped 57% to 6.76 billion rupees ($73.8 million) for the quarter ended December 31 from 15.71 billion rupees a year earlier.

Analysts, on average, had expected 12.42 billion rupees, as per data compiled by LSEG.

($1 = 91.6200 Indian rupees)